Drug Profile
GC 3107A
Alternative Names: BCG vaccine - GC Biopharma; BCG vaccine - Green Cross; GC 3107; GC-3107ALatest Information Update: 18 Nov 2022
Price :
$50
*
At a glance
- Originator Green Cross
- Developer GC Biopharma
- Class Antituberculars; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Tuberculosis
Most Recent Events
- 06 Sep 2022 Green Cross Corporation completes a phase III clinical trials in Tuberculosis (In infants, Prevention) in South Korea (Intradermal, Injection) (NCT03947138)
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 01 Jul 2020 Phase-III clinical trials in Tuberculosis (Prevention) in South Korea (Intradermal) (GC Pharma's pipeline, January 2021)